PAP
RLMD icon

Persistent Asset Partners’s Relmada Therapeutics RLMD Stock Holding History

Persistent Asset Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$598K Buy
86,443
+35,670
+70% +$249K 0.18% 98
2026
Q1 		$353K Sell
50,773
-180,350
-78% -$853K 0.13% 137
2025
Q4 		$1.12M Buy
+231,123
New +$774K 0.5% 53

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Persistent Asset Partners's RLMD Position: Q2 2026 in Review

Persistent Asset Partners increased its Relmada Therapeutics (RLMD) stake by 70% in Q2 2026, buying an estimated $249K and bringing the position to 86,443 shares worth $598K. The position accounts for 0.18% of the portfolio, ranked #98.

Persistent Asset Partners first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.12M in Q4 2025. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Persistent Asset Partners held 86,443 shares of Relmada Therapeutics worth $598K as of Q2 2026.
  • Persistent Asset Partners bought 35,670 Relmada Therapeutics shares in Q2 2026, an estimated $249K.
  • Relmada Therapeutics made up 0.18% of Persistent Asset Partners's portfolio in Q2 2026, its #98 holding.
  • Persistent Asset Partners first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Relmada Therapeutics position peaked at $1.12M in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.